Radiopharm Theranostics Limited (RDPTF)

0.0008 0.0000 (0.00%) At close: 09:37AM EDT

Radiopharm Theranostics Limited

62 Lygon Street
Level 3
Carlton, VIC 3053
Australia
61 3 9824 5254
https://www.radiopharmtheranostics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD	Founder & Executive Chairman	179.73k	N/A	1956
Mr. Riccardo Canevari	MD, CEO & Director	997.14k	N/A	N/A
Mr. Vittorio Puppo M.D.	Chief Operating Officer	683.24k	N/A	N/A
Prof. David Mozley	Chief Medical Officer & Scientific Advisory Board Chair	507.01k	N/A	N/A
Dr. Thomas H. Tulip Ph.D.	Chief Business Officer	334.19k	N/A	1953
Mr. Phillip Hains	CFO, Company Secretary & Director	N/A	N/A	N/A
Dr. Scot L. Harper Ph.D.	Senior Vice President of Clinical Operations	N/A	N/A	1957
Mr. Bill Regan	Senior Vice President of Regulatory Strategy	N/A	N/A	N/A
Dr. Rama Abu Shmeis	Senior VP of Chemistry, Manufacturing & Controls	N/A	N/A	N/A
Mr. Nathan Jong C.A.	Company Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It is developing its lead products comprising Nano-mAbs and AVB6 Integrin. The company was incorporated in 2021 and is based in Carlton, Australia.

Corporate governance

Radiopharm Theranostics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.